Light chain (AL) Amyloidosis/Primary

Jun 03, 2018
Subcutaneous Daratumumab (DARA SC) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Patients (Pts) With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of Andromeda
Background: Systemic AL amyloidosis is characterized by disposition of insoluble amyloid fibrils into tissues and organs via clonal expansion of CD38+ plasma cells…
Read more
Apr 16, 2018
Left Ventricular Myocardial Deformation on Cine MR Images: Relationship to Severity of Disease and Prognosis in Light-Chain Amyloidosis
Purpose: To measure left ventricular (LV) myocardial strain with cine magnetic resonance (MR) imaging and a deformable registration algorithm (DRA) and to assess…
Read more
Mar 06, 2018
The Effect and Safety of Bortezomib in the Treatment of AL Amyloidosis: A Systematic Review and Meta-Analysis
Bortezomib began to be used in the treatment of light chain (AL) amyloidosis in recent years. We performed the first meta-analysis of randomized clinical trials and…
Read more
Sep 26, 2017
At Least Partial Hematological Response After First Cycle of Treatment Predicts Organ Response and Long-term Survival for Patients With AL Amyloidosis Receiving Bortezomib-Based Treatment
AL amyloidosis is a rare plasma cell dyscrasia characterized by multi-organ involvement and poor prognosis. We retrospectively evaluated the organ response (OR) and…
Read more
Apr 10, 2017
Disease Burden of Systemic Light-Chain Amyloidosis: A Systematic Literature Review
Introduction: A systematic literature review on systemic light chain (AL) amyloidosis was conducted in order to understand the disease burden, and identify unmet…
Read more
Subscribe to